Contrast of Response to Dacarbazine, Mitomycin, Doxorubicin, and Cisplatin (DMAP) Plus GM-CSF Between Patients with Advanced Malignant Gastrointestinal Stromal Tumors and Patients with Other Advanced Leiomyosarcomas

REFERENCES

• Borden E.C., Amato D.A., Rosenbaum C., Enterline H.T., Shiraki M.J., Creech R.H., Lerner H.J., Carbone P. Randomized Comparison of Three Adriamycin Regimens for Metastatic Soft Tissue Sarcomas. J. Clin. Oncol. 1987; 5: 840–850
   PubMed Web of Science ®Google Scholar
• Edmonson J.H., Ryan L.M., Blum R.H., Brooks J.S.J., Shiraki M., Parkinson D.R. Randomized Comparison of Doxorubicin Alone Versus Ifosfamide+Doxorubicin or Mitomycin+Doxorubicin+Cisplatin Against Advanced Soft Tissue Sarcomas. J. Clin. Oncol. 1993; 11: 1269–1275
   PubMed Web of Science ®Google Scholar
• Zalupski M., Metch B., Balcerzak S., Fletcher W.S., Chapman R., Bonnet J.D., Weiss G.R., Ryan J., Benjamin R.S., Baker L.H. Phase III Comparison of Doxorubicin and Dacarbazine Given by Bolus Versus Infusion in Patients with Soft-Tissue Sarcomas: A Southwest Oncology Group Study. J. Natl Cancer Inst. 1991; 83: 926–932
   PubMed Web of Science ®Google Scholar
• Lerner H., Amato D., Stevens C., Border E., Enterline H. Leiomyosarcoma: The Eastern Cooperative Oncology Group Experience with 222 Patients. Proc. Am. Assoc. Cancer Res. 1983; 142
   Web of Science ®Google Scholar
• Edmonson J.H., Hartmann L.C., Long H.J., Colon-Otero G., Fitch T.R., Jefferies J.A., Braich T.A., Maples W.J. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF): Preliminary Observations on the Influences of Dose, Schedule, and Route of Administration in Patients Receiving Cyclophosphamide Plus Carboplatin. Cancer 1992; 70: 2529–2539
   PubMed Web of Science ®Google Scholar
• Dispenzieri A., Loprinzi C. Chemotherapy-Induced Insulin Dependent Diabetes Mellitus. J. Clin. Oncol. 1997; 15: 1287
   PubMed Web of Science ®Google Scholar
• Sircar K., Hewlett B.R., Huizinga J.D., Chorneyko K., Barezin I., Riddell R.H. Interstitial Cells of Cajal as Precursors of Gastrointestinal Stromal Tumors. Am. J. Surg. Pathol. 1999; 23: 377–389
   PubMed Web of Science ®Google Scholar
• Plaat B.E.C., Hollema H., Molenaar W.M., Torn Broers G.H., Pijpe J, Mastik M.F., Hoekstra H.J., van den Berg E., Scheper R.J., van der Graaf W.T.A. Soft Tissue Leiomyosarcomas and Malignant Gastrointestinal Stromal Tumors: Differences in Clinical Outcome and Expression of Multidrug Resistance Proteins. J. Clin. Oncol. 2000; 18: 3211–3220
   PubMed Web of Science ®Google Scholar
• Omura G.A., Major F.J., Blessing J.A., Sedlocek T.V., Thigpen J.T., Creasman W.T., Zaino R.J. A Randomized Study of Adriamycin with and without Dimethyl Triazenoimidazole Carboxamide in Advanced Uterine Sarcomas. Cancer 1983; 52: 626–632
   PubMed Web of Science ®Google Scholar
• Muss H.B., Bundy B., DiSaia P.J., Homesley H.D., Fowler W.C., Creasman W., Yordan E. Treatment of Recurrent or Advanced Uterine Sarcoma. A Randomized Trial of Doxorubicin Versus Doxorubicin and Cyclophosphamide (A Phase III Trial of the Gynecologic Oncology Group). Cancer 1985; 55: 1648–1653
   PubMed Web of Science ®Google Scholar
• Thigpen J.T., Blessing J.A., Beecham J., Homeley H., Yordan E. Phase II Trial of Cisplatin as First-Line Chemotherapy in Patients with Advanced or Recurrent Uterine Sarcomas: A Gynecologic Oncology Group Study. J. Clin. Oncol. 1991; 9: 1962–1966
   PubMed Web of Science ®Google Scholar
• Sutton G.P., Blessing J.A., Barrett R.J., McGhee R. Phase II Trial of Ifosfamide and Mesna in Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study. Am. J. Obstet. Gynecol. 1992; 166: 556–559
   PubMed Web of Science ®Google Scholar
• Sutton G., Blessing J.A., Malfetano J.H. Ifosfamide and Doxorubicin in the Treatment of Advanced Leiomyosarcomas of the Uterus: A Gynecologic Oncology Group Study. Gynecol. Oncol. 1996; 62: 226–229
   PubMed Web of Science ®Google Scholar
• Slayton R.E., Blessing J.A., Angel C., Berman M. Phase II Trial of Etoposide in the Management of Advanced Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study. Cancer Treat. Rep. 1987; 71: 1303–1304
   PubMedGoogle Scholar
• Thigpen T., Blessing J.A., Yordan E., Valea F., Vaccarello L. Phase II Trial of Etoposide in Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study. Gynecol. Oncol. 1996; 63: 120–122
   PubMed Web of Science ®Google Scholar
• Rose P.G., Blessing J.A., Soper J.T., Barter J.F. Prolonged Oral Etoposide in Recurrent or Advanced Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study. Gynecol. Oncol. 1998; 70: 267–271
   PubMed Web of Science ®Google Scholar
• Muss H.B., Bundy B.N., Adcock L., Beecham J. Mitoxantrone in the Treatment of Advanced Uterine Sarcoma. Am. J. Clin. Oncol. 1990; 13: 32–34
   PubMed Web of Science ®Google Scholar
• Slayton R.E., Blessing J.A., Look K., Anderson B. A Phase II Clinical Trial of Diaziquone (AZQ) in the Treatment of Patients with Recurrent Leiomyosarcoma of the Uterus (A Gynecologic Oncology Group Study). Invest. N. Drugs 1991; 9: 207–208
   PubMed Web of Science ®Google Scholar
• Asbury R., Blessing J.A., Smith D., Carson L.F. Aminothiadiazole in the Treatment of Patients with Metastatic Leiomyosarcoma of the Uterine Corpus: A Gynecologic Oncology Group Study. Am. J. Clin. Oncol. 1995; 18: 397–399
   PubMed Web of Science ®Google Scholar
• Asbury R., Blessing J.A., Buller R., Malfetano J.H., Walker J., Sevin B.U. Amonafide in Patients with Leiomyosarcoma of the Uterus: A Phase II Gynecologic Oncology Group Study. Am. J. Clin. Oncol. 1998; 21: 145–146
   PubMed Web of Science ®Google Scholar
• Currie J.L., Blessing J.A., Muss H.B., Fowler J., Berman M., Burke T.W. Combination Chemotherapy with Hydroxyurea, Dacarbazine (DTIC), and Etoposide in the Treatment of Uterine Leiomyosarcoma: A Gynecologic Oncology Group Study. Gynecol. Oncol. 1996; 61: 27–30
   PubMed Web of Science ®Google Scholar